Rilzabrutinib improved efficacy and QOL outcomes among pre-treated adult patients with immune thrombocytopenia.
Hydroxyurea showed more dose-limiting toxicities than placebo but reduced clinical AEs and improved hematological parameters, ...
The holiday season increases cardiac risks and reduces medical access, making proactive cardiac health strategies essential ...
Revumenib displayed promising anti-tumor activity among patients with relapsed or refractory KMT2Ar acute leukemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback